Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased a 323,930-square-foot industrial building in the ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

RCCC News Service SALISBURY — Rowan-Cabarrus Community College and its students recently benefited from involvement with Eli Lilly and Company and its annual Global Day of Service. Student ...

Eli Lilly shares sank 10% Wednesday morning after its third-quarter results came in well below what analysts were expecting.

Both treatments mimic certain gut hormones to tamp down a person's appetite and regulate their blood sugar. The popularity of those injectable drugs has forced both Eli Lilly and Novo Nordisk to ...